Literature DB >> 17526802

Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.

R Joshi1, D Horncastle, K Elderfield, I Lampert, A Rahemtulla, K N Naresh.   

Abstract

AIMS: Multiple myeloma (MM) guidelines in the UK do not advocate performing bone marrow trephine biopsy (BMTB) during follow-up. In a recent study, it was found that the plasma cell per cent (PC%) in BMTB performed at the time of autologous stem cell transplant strongly correlated with survival. The current study addresses whether BMTB is superior to bone marrow aspiration (BMA) in documenting presence of disease and its volume at follow-up.
METHODS: The study involved 106 samples. A conventional 500-cell differential count was performed on the BMAs to document the PC%. The PC% on BMTBs had been estimated on CD138 immunostain. Furthermore, BMTBs had also been immunostained for CD56, cyclin D1 and light chains.
RESULTS: The mean (2SEM) PC% values in BMAs and BMTBs were 13.1 (2.6)% and 31.8 (5.8)% respectively. Based on BMA, BMTB and serum/urine paraprotein or light chain estimation, on 92 occasions (89%) there was detectable disease. The positive predictive value of both BMA and BMTB was 100%, and the negative predictive values for BMTB and BMA were 57% and 22% respectively. Among 98 secretory MM cases, the BMTB-PC% showed significant correlation with paraprotein levels, whereas BMA-PC% did not.
CONCLUSIONS: It is strongly recommended that BMTB is performed and adequately investigated with immunohistochemistry during follow-up of MM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526802     DOI: 10.1136/jcp.2007.049130

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique.

Authors:  M Santra; J D Shaughnessy; W T Bellamy
Journal:  Biotech Histochem       Date:  2010-05-03       Impact factor: 1.718

Review 2.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

Review 3.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

4.  Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories.

Authors:  Shashirekha Shetty; Marion Siady; Kalyan C Mallempati; Andrew Wilson; Jeff Poarch; Brandon Chandler; Judy Gray; Mohamed E Salama
Journal:  Int J Hematol       Date:  2012-02-11       Impact factor: 2.490

5.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

6.  Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma.

Authors:  N Lee; S Y Moon; J-H Lee; H-K Park; S-Y Kong; S-M Bang; J H Lee; S-S Yoon; D S Lee
Journal:  Blood Cancer J       Date:  2017-02-17       Impact factor: 11.037

Review 7.  Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Authors:  Alessandra Romano; Giuseppe Alberto Palumbo; Nunziatina Laura Parrinello; Concetta Conticello; Marina Martello; Carolina Terragna
Journal:  Front Oncol       Date:  2019-08-20       Impact factor: 6.244

8.  Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.

Authors:  Mihai Merzianu; Adrienne Groman; Alan Hutson; Claudiu Cotta; Russell K Brynes; Attilio Orazi; Vishnu Reddy; Julie Teruya-Feldstein; Ramila Amre; Manjula Balasubramanian; Guilherme Brandao; Sindhu Cherian; Elizabeth Courville; David Czuchlewski; Guang Fan; David Grier; Daniela Hoehn; Kedar V Inamdar; Ridas Juskevicius; Prabhjot Kaur; John Lazarchick; Michael R Lewis; Rodney R Miles; Jerome B Myers; Michel R Nasr; Hina N Qureishi; Horatiu Olteanu; Valentin G Robu; Gratian Salaru; Neerja Vajpayee; Jeffrey Vos; Ling Zhang; Shanxiang Zhang; Le Aye; Elisa Brega; James E Coad; John Grantham; Sinisa Ivelja; Robert McKenna; Kieran Sultan; Gregory Wilding; Robert Hutchison; LoAnn Peterson; Richard T Cheney
Journal:  Am J Clin Pathol       Date:  2018-10-01       Impact factor: 2.493

9.  Heparanase regulates levels of syndecan-1 in the nucleus.

Authors:  Ligong Chen; Ralph D Sanderson
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

10.  Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.

Authors:  Svitlana Demyanets; Alexandra Kaider; Ingrid Simonitsch-Klupp; Günther Bayer; Almira Subasic; Renate Thalhammer; Harald Esterbauer; Maria T Krauth; Hermine Agis; Thomas Reiter; Ilse Schwarzinger
Journal:  Ann Hematol       Date:  2020-09-15       Impact factor: 3.673

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.